Company intelligence / Profile preview

Allios Pharma

Overview

Allos Pharma has received FDA guidance for the design of a Phase 3 trial to support a New Drug Application for the treatment of Fragile X Syndrome[1]

1 asset

Phase 3

Indications: Autism Spectrum Disorder, Fragile X Syndrome, 16p11.2 deletion syndrome

U.S. Food and Drug Administration (FDA)

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Allios Pharma.